1-dimethylcarbamoylmethyl-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid | 1437323-74-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-dimethylcarbamoylmethyl-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid
• 英文别名: 1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid；1-[2-(Dimethylamino)-2-oxoethyl]-3-(4-fluorophenyl)-2,4-dioxopyrimidine-5-carboxylic acid
• CAS: 1437323-74-4
• 化学式: C₁₅H₁₄FN₃O₅
• 分子量: 335.292
• InChiKey: CVRABLBHGAEPFZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  98.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-dimethylcarbamoylmethyl-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid 在 copper(l) iodide 、 四(三苯基膦)钯 、 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 生成 N-(4-((2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
  参考文献：
  名称：

  [EN] PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF
  [FR] COMPOSÉS À BASE DE PYRIMIDINEDIONE UTILISÉS EN TANT QU'INHIBITEURS D'AXL, C-MET ET MER ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  Provided is an inhibitor of AXL, Mer, and/or c-Met of Formula (I) or a pharmaceutically acceptable salt thereof: Formula (I), in which R1, R2, R3, G, and Q are described herein. Further provided is a method of treating or preventing an AXL-, Mer-, and/or c-Met-mediated disease using an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. When AXL, MER, and/or c-Met is inhibited, the compound or pharmaceutically acceptable salt thereof can re-sensitize cancer cells, such as non-small cell lung cancer cells, that have grown resistant to an anti-cancer agent.

  公开号：

  WO2023156863A1
• 作为产物：
  描述：

  ethyl 1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 在 盐酸 、 水 作用下， 以 1,4-二氧六环 为溶剂， 以81 %的产率得到1-dimethylcarbamoylmethyl-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid
  参考文献：
  名称：

  [EN] PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF
  [FR] COMPOSÉS À BASE DE PYRIMIDINEDIONE UTILISÉS EN TANT QU'INHIBITEURS D'AXL, C-MET ET MER ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  Provided is an inhibitor of AXL, Mer, and/or c-Met of Formula (I) or a pharmaceutically acceptable salt thereof: Formula (I), in which R1, R2, R3, G, and Q are described herein. Further provided is a method of treating or preventing an AXL-, Mer-, and/or c-Met-mediated disease using an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. When AXL, MER, and/or c-Met is inhibited, the compound or pharmaceutically acceptable salt thereof can re-sensitize cancer cells, such as non-small cell lung cancer cells, that have grown resistant to an anti-cancer agent.

  公开号：

  WO2023156863A1

文献信息

• [EN] URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'URACILE COMME INHIBITEURS D'AXL ET C-MET KINASES
  申请人：CEPHALON INC

  公开号：WO2013074633A1

  公开（公告）日：2013-05-23

  The present invention provides compounds of Formula I, or pharmaceutically acceptable salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c,Y, R3, X, E and G are as defined herein, methods of treatment and uses thereof.

  本发明提供了式I的化合物，或其药用盐形式，其中Ra、Rb、Rc、Rd、D、W、R1a、R1b、R1c、Y、R3、X、E和G的定义如本文所述，以及其治疗方法和用途。
• URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS
  申请人：Ignyta, Inc.

  公开号：US20150209358A1

  公开（公告）日：2015-07-30

  The present application provides compounds of Formula I or salt forms thereof, wherein R a , R b , R c , R d , D, W, R 1a , R 1b , R 1c , Y, R 3 , X, E and G are as defined herein, compositions, methods of treatment and uses thereof.

  本申请提供了I式化合物或其盐形式，其中Ra、Rb、Rc、Rd、D、W、R1a、R1b、R1c、Y、R3、X、E和G的定义如本文所述，以及其组合物、治疗方法和用途。
• Uracil derivatives as AXL and c-MET kinase inhibitors
  申请人：IGNYTA, INC.

  公开号：US10017496B2

  公开（公告）日：2018-07-10

  The present invention provides compounds of Formula I or pharmaceutically acceptable salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c, Y, R3, X, E and G are as defined herein, methods of treatment and uses thereof.

  本发明提供了式 I 的化合物 或其药学上可接受的盐形式，其中 Ra、Rb、Rc、Rd、D、W、R1a、R1b、R1c、Y、R3、X、E 和 G 如本文所定义；以及其治疗方法和用途。
• US20140275077A1
  申请人：——

  公开号：US20140275077A1

  公开（公告）日：2014-09-18
• US9029538B2
  申请人：——

  公开号：US9029538B2

  公开（公告）日：2015-05-12